Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free BNTC Stock Alerts

Benitec Biopharma (BNTC) Financials

Benitec Biopharma logo
$11.02 -0.34 (-2.99%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$11.00 -0.03 (-0.23%)
As of 09/18/2026 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Benitec Biopharma

Annual Income Statements for Benitec Biopharma

This table shows Benitec Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 2.61 -8.27 -14 -18 -20 -22 -38 -46
Consolidated Net Income / (Loss)		 2.61 -8.27 -14 -18 -20 -22 -38 -46
Net Income / (Loss) Continuing Operations		 2.61 -8.27 -14 -18 -20 -22 -38 -46
Total Pre-Tax Income 		2.61 -8.27 -14 -18 -20 -22 -38 -46
Total Operating Income		 2.58 -8.28 -14 -18 -19 -22 -42 -51
Total Gross Profit		 12 0.10 0.06 0.07 0.08 0.00 0.00 0.00
Total Revenue		 12 0.10 0.06 0.07 0.08 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 9.62 8.38 14 18 19 22 42 51
Selling, General & Admin Expense		 4.61 5.57 6.51 6.65 6.38 6.99 23 28
Research & Development Expense		 4.57 3.00 7.02 11 13 16 18 23
Total Other Income / (Expense), net		 0.03 0.01 -0.29 -0.35 -0.48 0.74 3.85 5.65
Interest Expense		 - - - - - 0.00 -0.76 0.00
Interest & Investment Income		 0.12 0.06 -0.01 -0.03 -0.03 0.90 3.29 5.57
Other Income / (Expense), net		 -0.10 -0.06 -0.28 -0.32 -0.45 -0.17 -0.20 0.08
Basic Earnings per Share		 $3.05 ($8.10) ($3.23) ($37.88) ($14.12) ($1.22) ($1.05) ($0.98)
Weighted Average Basic Shares Outstanding		 856.77K 1.02M 4.30M 480.69K 1.39M 18.36M 36.21M 46.56M
Diluted Earnings per Share		 $3.05 ($8.10) ($3.23) ($37.88) ($14.12) ($1.22) ($1.05) ($0.98)
Weighted Average Diluted Shares Outstanding		 856.77K 1.02M 4.30M 480.69K 1.39M 18.36M 36.21M 46.56M
Weighted Average Basic & Diluted Shares Outstanding		 856.77K 1.02M 4.30M 8.17M 2.55M 10.56M 26.25M 34.88M

Quarterly Income Statements for Benitec Biopharma

This table shows Benitec Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q3 2025 Q1 2026 Q3 2026
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2024 3/31/2024 6/30/2024 9/30/2024 3/31/2025 9/30/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -5.41 -4.40 -4.66 -6.57 -7.36 -4.28 -5.34 -5.06 -15 -8.97 -12
Consolidated Net Income / (Loss)		 -5.41 -4.40 -4.66 -5.95 -7.36 -4.28 -4.72 -5.06 -15 -8.97 -12
Net Income / (Loss) Continuing Operations		 -5.41 -4.40 -4.66 -5.95 -7.36 -4.28 -4.72 -5.06 -15 -8.97 -12
Total Pre-Tax Income 		-5.41 -4.40 -4.66 -5.95 -7.36 -4.28 -4.72 -5.06 -15 -8.97 -12
Total Operating Income		 -5.61 -4.34 -4.55 -5.87 -8.61 -4.14 -5.55 -5.79 -15 -9.80 -14
Total Gross Profit		 0.01 0.05 0.01 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Revenue		 0.01 0.05 0.01 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Operating Expenses		 5.62 4.40 4.56 5.87 8.61 4.14 5.55 5.79 15 9.80 14
Selling, General & Admin Expense		 1.86 1.23 1.37 1.55 3.54 1.58 2.04 2.21 8.84 6.43 7.28
Research & Development Expense		 3.76 3.17 3.19 4.43 5.07 2.57 3.51 3.59 6.50 3.37 6.30
Total Other Income / (Expense), net		 0.20 -0.06 -0.11 -0.08 1.25 -0.14 0.83 0.73 0.83 0.84 1.65
Interest Expense		 - - - - -0.76 0.00 - - 0.00 - 0.00
Interest & Investment Income		 -0.01 -0.01 -0.01 -0.01 0.82 -0.00 0.92 0.60 0.82 1.01 1.59
Other Income / (Expense), net		 0.21 -0.05 -0.10 -0.07 -0.33 -0.13 -0.09 0.13 0.01 -0.17 0.05
Basic Earnings per Share		 ($3.34) ($2.67) ($3.36) ($3.05) ($0.33) ($0.23) ($1.31) ($0.18) ($0.38) ($0.22) ($0.24)
Weighted Average Basic Shares Outstanding		 1.62M 1.65M 1.39M 2.16M 22.08M 18.28M 4.06M 27.88M 38.60M 41.52M 49.39M
Diluted Earnings per Share		 ($3.34) ($2.67) ($3.36) ($3.05) ($0.33) ($0.23) ($1.31) ($0.18) ($0.38) ($0.22) ($0.24)
Weighted Average Diluted Shares Outstanding		 1.62M 1.65M 1.39M 2.16M 22.08M 18.28M 4.06M 27.88M 38.60M 41.52M 49.39M
Weighted Average Basic & Diluted Shares Outstanding		 27.98M 27.98M 2.55M 2.57M 23.45M 9.37M 10.56M 23.22M 25.60M 33.86M 34.35M

Annual Cash Flow Statements for Benitec Biopharma

This table details how cash moves in and out of Benitec Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Net Change in Cash & Equivalents		 4.39 -5.86 9.97 -16 -1.59 48 47 82
Net Cash From Operating Activities		 4.79 -7.54 -13 -16 -18 -19 -24 -17
Net Cash From Continuing Operating Activities		 4.79 -7.54 -13 -16 -18 -19 -24 -17
Net Income / (Loss) Continuing Operations		 2.61 -8.27 -14 -18 -20 -22 -38 -46
Consolidated Net Income / (Loss)		 2.61 -8.27 -14 -18 -20 -22 -38 -46
Depreciation Expense		 0.16 0.19 0.23 0.17 0.14 0.09 0.07 0.06
Amortization Expense		 0.00 0.18 0.19 0.23 0.25 0.26 0.33 0.42
Non-Cash Adjustments To Reconcile Net Income		 0.70 0.07 0.43 0.88 0.46 0.83 17 26
Changes in Operating Assets and Liabilities, net		 1.32 0.30 0.20 1.04 0.71 1.17 -2.73 2.14
Net Cash From Investing Activities		 -0.40 -0.09 -0.22 -0.01 -0.00 -0.18 -0.02 -0.11
Net Cash From Continuing Investing Activities		 -0.40 -0.09 -0.22 -0.01 -0.00 -0.18 -0.02 -0.11
Purchase of Property, Plant & Equipment		 -0.40 -0.10 -0.22 -0.01 -0.00 -0.18 -0.02 -0.11
Net Cash From Financing Activities		 0.00 1.77 23 0.00 16 68 70 99
Net Cash From Continuing Financing Activities		 0.00 1.77 23 0.00 16 68 70 99
Repurchase of Common Equity		 0.00 -0.48 -3.23 0.00 -1.87 -5.89 -2.32 -6.27
Issuance of Common Equity		 0.00 2.25 26 0.00 18 71 30 104
Other Financing Activities, net		 - - - - - 3.04 42 0.75
Effect of Exchange Rate Changes		 - - - 0.20 0.41 -0.01 0.05 -0.13

Quarterly Cash Flow Statements for Benitec Biopharma

This table details how cash moves in and out of Benitec Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q4 2025 Q1 2026 Q4 2026
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 6/30/2025 9/30/2025 6/30/2026
Net Change in Cash & Equivalents		 -6.00 -3.99 -4.08 23 -5.49 -6.23 37 17 -5.79 -3.27 -4.79
Net Cash From Operating Activities		 -5.84 -4.03 -4.10 -4.58 -5.37 -6.17 -3.29 -4.59 -8.21 -3.35 -4.94
Net Cash From Continuing Operating Activities		 -5.84 -4.03 -4.10 -4.58 -5.37 -6.17 -3.29 -4.59 -8.21 -3.35 -4.94
Net Income / (Loss) Continuing Operations		 -5.41 -4.40 -4.66 -5.95 -6.80 -4.28 -4.72 -5.06 -16 -8.97 -13
Consolidated Net Income / (Loss)		 -5.41 -4.40 -4.66 -5.95 -6.80 -4.28 -4.72 -5.06 -16 -8.97 -13
Depreciation Expense		 0.04 0.03 0.02 0.02 0.02 0.03 0.03 0.03 0.01 0.01 0.02
Amortization Expense		 0.06 0.06 0.06 0.06 0.06 0.07 0.07 0.07 0.10 0.11 0.11
Non-Cash Adjustments To Reconcile Net Income		 -0.11 0.01 0.31 0.09 0.09 0.19 0.45 0.36 13 5.18 6.26
Changes in Operating Assets and Liabilities, net		 -0.43 0.26 0.17 1.20 1.26 -2.17 0.88 0.02 -5.28 0.32 1.49
Net Cash From Investing Activities		 - - -0.00 0.00 - -0.18 - 0.00 - 0.00 -0.08
Net Cash From Continuing Investing Activities		 - - -0.00 0.00 - -0.18 - 0.00 - 0.00 -0.08
Purchase of Property, Plant & Equipment		 - - -0.00 - - - - - - - -0.08
Net Cash From Financing Activities		 - - - 28 0.04 - 40 22 2.54 0.00 0.24
Net Cash From Continuing Financing Activities		 - - - 28 0.04 - 40 22 2.54 0.00 0.24
Other Financing Activities, net		 - - - 31 0.04 - - 22 2.62 0.00 0.24
Effect of Exchange Rate Changes		 -0.15 0.04 0.02 0.05 -0.16 0.12 -0.01 -0.10 -0.12 0.09 -0.01

Annual Balance Sheets for Benitec Biopharma

This table presents Benitec Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Total Assets		 19 12 21 5.97 4.46 52 100 183
Total Current Assets		 19 11 21 4.82 3.73 52 99 182
Cash & Equivalents		 16 9.80 20 4.06 2.48 51 98 180
Restricted Cash		 - - 0.02 0.01 0.01 0.06 0.11 0.11
Accounts Receivable		 2.54 0.06 0.03 0.00 0.06 0.23 0.03 0.00
Prepaid Expenses		 - - 0.80 0.74 1.18 0.52 0.63 1.60
Plant, Property, & Equipment, net		 0.47 0.37 0.38 0.22 0.09 0.18 0.13 0.18
Total Noncurrent Assets		 0.01 0.40 0.40 0.93 0.65 0.36 0.94 0.76
Other Noncurrent Operating Assets		 0.01 0.40 0.40 0.93 0.65 0.36 0.94 0.76
Total Liabilities & Shareholders' Equity		 19 12 21 5.97 4.46 52 100 183
Total Liabilities		 2.64 1.35 1.37 3.09 4.26 4.96 2.30 5.61
Total Current Liabilities		 2.64 1.14 1.37 2.53 3.98 4.92 1.80 5.34
Accounts Payable		 2.49 0.74 0.88 1.88 3.23 4.17 1.02 4.30
Current Employee Benefit Liabilities		 0.15 0.20 0.28 0.40 0.47 0.48 0.43 0.55
Other Current Liabilities		 0.00 0.19 0.21 0.25 0.28 0.28 0.35 0.50
Total Noncurrent Liabilities		 0.00 0.21 0.00 0.56 0.28 0.04 0.50 0.27
Other Noncurrent Operating Liabilities		 0.00 0.21 0.00 0.56 0.28 0.00 0.50 0.27
Total Equity & Noncontrolling Interests		 17 10 20 2.88 0.20 47 97 177
Total Preferred & Common Equity		 17 10 20 2.88 0.20 47 97 177
Preferred Stock		 - - - - - 0.00 0.00 0.00
Total Common Equity		 17 10 20 2.88 0.20 47 97 177
Common Stock		 127 129 152 152 169 238 326 452
Retained Earnings		 -109 -117 -130 -148 -168 -190 -228 -274
Accumulated Other Comprehensive Income / (Loss)		 -1.86 -1.95 -1.46 -1.25 -0.83 -0.89 -0.84 -0.96

Quarterly Balance Sheets for Benitec Biopharma

This table presents Benitec Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q3 2025 Q1 2026 Q3 2026
Period end date 3/31/2022 9/30/2022 12/31/2022 3/31/2023 9/30/2023 12/31/2024 3/31/2024 9/30/2024 3/31/2025 9/30/2025 3/31/2026
Total Assets		 10 18 12 8.22 27 79 15 69 105 96 187
Total Current Assets		 8.84 17 11 7.40 26 79 14 68 104 95 186
Cash & Equivalents		 8.63 17 11 6.55 26 78 14 68 104 94 185
Restricted Cash		 - 0.01 0.01 0.01 0.01 0.06 0.01 0.06 0.06 0.11 0.11
Accounts Receivable		 0.01 0.00 0.07 0.06 0.05 0.00 0.05 0.00 0.00 0.01 0.00
Prepaid Expenses		 0.21 0.53 0.36 0.77 0.48 0.37 0.16 0.43 0.36 0.48 1.14
Plant, Property, & Equipment, net		 0.21 0.18 0.14 0.11 0.07 0.15 0.20 0.15 0.15 0.12 0.12
Total Noncurrent Assets		 1.01 0.86 0.79 0.72 0.57 0.20 0.43 0.29 1.05 0.83 0.87
Other Noncurrent Operating Assets		 1.01 0.86 0.79 0.72 0.57 0.20 0.43 0.29 1.05 0.83 0.87
Total Liabilities & Shareholders' Equity		 10 18 12 8.22 27 79 15 69 105 96 187
Total Liabilities		 2.54 3.50 2.91 3.51 4.75 3.13 3.50 4.59 7.64 2.43 3.67
Total Current Liabilities		 1.91 3.01 2.49 3.15 4.53 3.09 3.44 4.55 7.03 2.03 3.27
Accounts Payable		 1.32 2.37 1.83 2.46 3.79 2.42 2.63 3.85 6.25 1.15 2.25
Current Employee Benefit Liabilities		 0.36 0.39 0.40 0.43 0.46 0.54 0.52 0.50 0.43 0.46 0.54
Other Current Liabilities		 0.23 0.26 0.26 0.27 0.28 0.14 0.29 0.21 0.35 0.41 0.48
Total Noncurrent Liabilities		 0.64 0.49 0.42 0.35 0.21 0.04 0.06 0.04 0.61 0.40 0.39
Other Noncurrent Operating Liabilities		 0.64 0.49 0.42 0.35 0.21 - 0.06 - 0.61 0.40 0.39
Total Equity & Noncontrolling Interests		 7.52 15 8.99 4.71 22 76 12 64 98 94 183
Total Preferred & Common Equity		 7.52 15 8.99 4.71 22 76 12 64 98 94 183
Preferred Stock		 - - - - - 0.00 - - 0.00 0.00 0.00
Total Common Equity		 7.52 15 8.99 4.71 22 76 12 64 98 94 183
Common Stock		 152 169 169 169 197 279 197 260 310 331 445
Retained Earnings		 -143 -153 -159 -163 -174 -203 -185 -195 -212 -237 -261
Accumulated Other Comprehensive Income / (Loss)		 -1.51 -0.74 -0.90 -0.85 -0.78 -0.69 -0.84 -0.99 -0.72 -0.75 -0.95

Annual Metrics And Ratios for Benitec Biopharma

This table displays calculated financial ratios and metrics derived from Benitec Biopharma's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
DEI Shares Outstanding		 0.00 0.00 7,854,416.00 - - - 25,600,210.00 34,354,334.00
DEI Adjusted Shares Outstanding		 0.00 0.00 462,024.00 - - - 25,600,210.00 34,354,334.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -30.05 - - - -1.48 -1.33
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% -99.16% -42.16% 23.73% 2.74% -100.00% 0.00% 0.00%
EBITDA Growth		 0.00% -401.02% -68.95% -32.20% -7.67% -16.52% -86.32% -21.80%
EBIT Growth		 0.00% -435.18% -66.46% -30.99% -7.44% -16.01% -85.24% -21.80%
NOPAT Growth		 0.00% -324.42% -64.18% -31.32% -6.87% -17.87% -85.70% -22.57%
Net Income Growth		 0.00% -417.13% -67.78% -31.16% -7.44% -11.19% -74.32% -20.12%
EPS Growth		 0.00% -365.57% 60.12% -31.16% -7.44% 60.98% 13.93% 6.67%
Operating Cash Flow Growth		 0.00% -257.31% -70.30% -23.90% -13.29% -7.72% -21.57% 29.97%
Free Cash Flow Firm Growth		 0.00% 0.00% -73.70% -19.04% -10.70% -17.02% -125.47% -2.99%
Invested Capital Growth		 0.00% -50.11% -48.28% -628.32% -91.62% -60.88% 84.73% -446.80%
Revenue Q/Q Growth		 0.00% 0.00% 156.52% 0.00% 10.29% -100.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -7.44% -7.26% 2.17% -4.59% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% -7.32% -6.84% 2.03% -4.56% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% -7.61% -5.20% 0.97% -4.64% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% -8.33% -6.21% 2.03% -0.27% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 22.73% -6.21% 2.03% 33.53% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -18.60% 1.86% 4.05% 3.97% -26.36% 16.54%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 6.34% 3.79% -0.77% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 121.36% -7.57% -23.54% -38.59% 0.00% 0.00%
Profitability Metrics		 - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00%
EBITDA Margin		 21.68% -7,805.88% -22,800.00% -24,361.64% -25,530.67% 0.00% 0.00% 0.00%
Operating Margin		 21.17% -8,118.63% -23,044.07% -24,457.53% -25,441.33% 0.00% 0.00% 0.00%
EBIT Margin		 20.39% -8,172.55% -23,518.64% -24,898.63% -26,038.67% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 21.39% -8,111.76% -23,528.81% -24,942.47% -26,082.67% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 104.91% 99.26% 100.04% 100.18% 100.17% 96.01% 90.35% 89.11%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 294.86% -882.97% -2,870.95% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 294.70% -863.56% -2,841.44% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -279.14% 821.30% 2,779.16% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 15.72% -61.67% -91.79% -159.08% -1,268.61% -91.68% -52.46% -33.21%
Cash Return on Invested Capital (CROIC)		 0.00% -816.10% -2,807.30% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 12.93% -54.09% -84.18% -132.90% -374.23% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 13.56% -53.69% -84.22% -133.14% -374.86% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 15.72% -61.67% -91.79% -159.08% -1,268.61% -91.68% -52.46% -33.21%
Return on Equity Simple (ROE_SIMPLE)		 15.72% -80.82% -69.38% -631.78% 0.00% -46.04% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 2.58 -5.80 -9.52 -12 -13 -16 -29 -36
NOPAT Margin		 21.17% -5,683.04% -16,130.85% -17,120.27% -17,808.93% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.17% -19.42% -29.51% -47.86% -189.01% -22.49% -11.67% -6.99%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -30.05% -20.24%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 37.82% 5,457.84% 11,037.29% 9,104.11% 8,509.33% 0.00% 0.00% 0.00%
R&D to Revenue		 37.44% 2,942.16% 11,898.31% 15,441.10% 17,032.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 78.83% 8,218.63% 23,144.07% 24,557.53% 25,541.33% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 2.49 -8.34 -14 -18 -20 -23 -42 -51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 2.65 -7.96 -13 -18 -19 -22 -42 -51
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 1.67 3.29 33.04 1.39 3.08 2.60
Price to Tangible Book Value (P/TBV)		 0.00 0.00 1.67 3.29 33.04 1.39 3.08 2.60
Price to Revenue (P/Rev)		 0.00 0.00 565.78 129.85 88.98 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 60.16 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 230.46 74.02 55.78 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.95 -0.95 -0.98 -1.04 -2.13 -1.13 -1.03 -1.01
Leverage Ratio		 1.16 1.15 1.09 1.19 3.38 1.19 1.05 1.03
Compound Leverage Factor		 1.22 1.14 1.09 1.20 3.39 1.15 0.95 0.92
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 5.05 -42.50 -66.20 2.46 74.81 47.30
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 7.10 9.52 15.05 1.90 0.94 10.49 54.67 34.00
Quick Ratio		 6.91 8.68 14.46 1.61 0.64 10.38 54.26 33.68
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -5.36 -9.31 -11 -12 -14 -32 -33
Operating Cash Flow to CapEx		 1,197.50% -8,015.96% -5,806.33% -122,300.00% -1,801,200.00% -10,839.66% -131,044.44% -15,731.43%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.63 0.01 0.00 0.01 0.01 0.00 0.00 0.00
Accounts Receivable Turnover		 4.81 0.08 1.40 5.21 2.59 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 25.96 0.24 0.16 0.24 0.49 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 75.88 4,643.01 259.83 70.00 141.13 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 75.88 4,643.01 259.83 70.00 141.13 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.88 0.44 0.23 -1.19 -2.29 -3.68 -0.56 -3.07
Invested Capital Turnover		 13.93 0.16 0.18 -0.15 -0.04 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -0.44 -0.21 -1.42 -1.09 -1.39 3.12 -2.51
Enterprise Value (EV)		 0.00 0.00 14 5.40 4.18 15 202 280
Market Capitalization		 0.00 0.00 33 9.48 6.67 65 300 460
Book Value per Share		 $19.37 $10.03 $2.55 $0.35 $0.01 $5.04 $3.80 $5.15
Tangible Book Value per Share		 $19.37 $10.03 $2.55 $0.35 $0.01 $5.04 $3.80 $5.15
Total Capital		 17 10 20 2.88 0.20 47 97 177
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -16 -9.80 -20 -4.08 -2.49 -51 -98 -180
Capital Expenditures (CapEx)		 0.40 0.09 0.22 0.01 0.00 0.18 0.02 0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.40 -0.13 -0.55 -1.79 -2.74 -4.18 -1.14 -3.75
Debt-free Net Working Capital (DFNWC)		 16 9.67 19 2.29 -0.25 47 97 176
Net Working Capital (NWC)		 16 9.67 19 2.29 -0.25 47 97 176
Net Nonoperating Expense (NNE)		 -0.03 2.48 4.36 5.71 6.21 6.01 8.68 9.71
Net Nonoperating Obligations (NNO)		 -16 -9.80 -20 -4.08 -2.49 -51 -98 -180
Total Depreciation and Amortization (D&A)		 0.16 0.37 0.42 0.39 0.38 0.34 0.40 0.48
Debt-free, Cash-free Net Working Capital to Revenue		 3.25% -125.49% -923.73% -2,449.32% -3,652.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 132.10% 9,483.33% 32,608.47% 3,134.25% -332.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 132.10% 9,483.33% 32,608.47% 3,134.25% -332.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $51.85 ($137.70) ($54.91) ($37.91) ($14.12) ($5.51) ($1.05) ($0.98)
Adjusted Weighted Average Basic Shares Outstanding		 50.40K 65.20K 480.69K 480.69K 1.39M 4.06M 36.21M 46.56M
Adjusted Diluted Earnings per Share		 $51.85 ($137.70) ($54.91) ($37.91) ($14.12) ($5.51) ($1.05) ($0.98)
Adjusted Weighted Average Diluted Shares Outstanding		 50.40K 65.20K 480.69K 480.69K 1.39M 4.06M 36.21M 46.56M
Adjusted Basic & Diluted Earnings per Share		 $51.85 ($137.70) ($54.91) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 50.40K 60.07K 252.67K 480.69K 2.55M 10.56M 26.25M 34.88M
Normalized Net Operating Profit after Tax (NOPAT)		 1.81 -5.80 -9.52 -12 -13 -16 -29 -36
Normalized NOPAT Margin		 14.82% -5,683.04% -16,130.85% -17,120.27% -17,808.93% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 21.39% -8,111.76% -23,528.81% -24,942.47% -26,082.67% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -5.80% -23.25% 0.00% -9.55% -27.09% -6.12% -13.76%

Quarterly Metrics And Ratios for Benitec Biopharma

This table displays calculated financial ratios and metrics derived from Benitec Biopharma's official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q3 2025 Q1 2026 Q3 2026
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2024 3/31/2024 6/30/2024 9/30/2024 3/31/2025 9/30/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - 23,451,475.00 26,250,469.00 33,862,226.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 23,451,475.00 26,250,469.00 33,862,226.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - -0.62 -0.34 -0.35
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -44.00% 12.50% 0.00% 0.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -12.84% -36.37% 8.51% -17.74% -67.25% 2.61% -21.45% 5.01% -265.29% -76.92% 11.71%
EBIT Growth		 -12.31% -34.46% 7.99% -16.99% -65.57% 2.62% -21.21% 4.79% -258.46% -76.16% 11.71%
NOPAT Growth		 -16.03% -25.46% 3.95% -28.25% -53.48% 4.61% -21.93% 1.41% -270.32% -69.28% 11.43%
Net Income Growth		 -12.24% -34.26% 8.01% -16.91% -35.96% 2.68% -1.27% 15.03% -238.89% -77.21% 17.70%
EPS Growth		 -12.24% -34.26% 8.01% 61.78% 90.12% 38.58% 61.01% 84.26% -65.22% -22.22% 36.84%
Operating Cash Flow Growth		 -74.73% -17.74% 15.65% -13.15% 8.18% -53.09% 19.58% -0.20% 0.00% 26.93% 0.00%
Free Cash Flow Firm Growth		 -202.62% 3.09% -10.29% -62.52% -34.09% 8.80% -19.11% -57.37% -249.19% -146.15% -91.95%
Invested Capital Growth		 -4.29% -66.85% -91.62% -84.54% -54.40% -43.41% -60.88% -4.37% -128.77% 73.34% 74.61%
Revenue Q/Q Growth		 0.00% 285.71% -87.04% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -6.38% 18.92% -6.33% -28.39% -51.11% 37.65% -32.59% -0.41% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 -6.25% 18.73% -5.99% -27.83% -50.37% 37.06% -31.93% -0.41% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 -22.49% 22.62% -4.81% -29.10% -46.58% 40.22% -33.98% -4.38% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 -6.24% 18.74% -6.00% -27.74% -23.56% 37.06% -10.31% -7.18% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 -6.24% 18.74% -6.00% 9.23% 89.18% 37.88% 20.12% 63.36% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -44.45% 31.05% -1.64% -11.77% -17.22% -14.97% 46.61% -39.27% 0.00% 59.20% 0.00%
Free Cash Flow Firm Q/Q Growth		 -153.48% 40.55% 8.96% -18.45% -109.14% -40.78% -18.90% -56.50% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 19.49% -18.95% -23.54% -55.99% 32.64% 45.99% -38.59% -1.20% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -37,857.14% -7,957.41% -65,271.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -40,071.43% -8,038.89% -65,000.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -38,585.71% -8,129.63% -66,471.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -38,650.00% -8,142.59% -66,585.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.17% 100.16% 100.17% 100.10% 82.26% 100.09% 83.69% 89.33% 94.63% 89.87% 88.22%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -190.08% -326.46% -1,268.61% -110.63% -52.67% -267.59% -91.68% -48.23% 0.00% -53.01% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -184.60% -60.47% -955.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -184.91% -60.57% -956.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -190.08% -326.46% -1,268.61% -110.63% -52.67% -267.59% -91.68% -48.23% 0.00% -53.01% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -209.54% -423.68% 0.00% -91.55% -29.46% -188.63% 0.00% -32.50% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.93 -3.04 -3.19 -4.11 -6.03 -2.90 -3.88 -4.05 -11 -6.86 -9.51
NOPAT Margin		 -28,050.00% -5,627.22% -45,500.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -12.97% -17.88% -44.96% -8.68% -2.99% -13.32% -3.13% -2.14% -6.39% -2.59% -1.68%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -7.94% - - - -11.00% -7.33% -5.19%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 13,307.14% 2,274.07% 19,585.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 26,864.29% 5,864.81% 45,514.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 40,171.43% 8,138.89% 65,100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.40 -4.39 -4.65 -5.95 -8.94 -4.28 -5.64 -5.66 -15 -9.98 -14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.30 -4.30 -4.57 -5.87 -8.86 -4.19 -5.55 -5.57 -15 -9.86 -14
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.53 1.25 33.04 0.35 3.86 1.18 1.39 1.51 3.13 3.93 1.52
Price to Tangible Book Value (P/TBV)		 0.53 1.25 33.04 0.35 3.86 1.18 1.39 1.51 3.13 3.93 1.52
Price to Revenue (P/Rev)		 76.72 86.37 88.98 102.63 4,806.94 1,944.33 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 55.78 0.00 3,522.60 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.15 -1.24 -2.13 -1.15 -1.05 -1.28 -1.13 -1.08 -1.08 -1.03 -1.03
Leverage Ratio		 1.31 1.49 3.38 1.22 1.07 1.43 1.19 1.11 1.10 1.04 1.04
Compound Leverage Factor		 1.31 1.50 3.39 1.22 0.88 1.43 1.00 0.99 1.04 0.94 0.92
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -18.33 -27.93 -55.20 -7.78 53.45 -14.99 3.53 9.53 0.00 88.37 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.41 2.35 0.94 5.83 25.48 4.18 10.49 15.01 14.80 46.95 56.82
Quick Ratio		 4.26 2.10 0.64 5.72 25.34 4.13 10.38 14.90 14.74 46.66 56.43
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.86 -2.30 -2.09 -2.48 -5.18 -2.09 -2.49 -3.90 -7.31 -9.59 -14
Operating Cash Flow to CapEx		 0.00% 0.00% -409,500.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 1.70 2.23 2.59 2.68 1.74 0.13 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.30 0.43 0.49 0.61 0.42 0.05 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 214.88 163.71 141.13 136.27 209.43 2,841.79 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 214.88 163.71 141.13 136.27 209.43 2,841.79 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.56 -1.85 -2.29 -3.57 -2.40 -2.66 -3.68 -3.73 -6.08 -0.99 -1.54
Invested Capital Turnover		 -0.04 -0.05 -0.04 -0.03 -0.03 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.06 -0.74 -1.09 -1.64 -0.85 -0.80 -1.39 -0.16 -3.42 2.73 4.53
Enterprise Value (EV)		 -5.79 -0.69 4.18 -18 215 -0.55 15 29 201 274 95
Market Capitalization		 4.76 5.87 6.67 7.70 293 14 65 97 305 368 280
Book Value per Share		 $0.32 $0.17 $0.01 $8.76 $3.27 $4.44 $5.04 $6.08 $4.16 $3.57 $6.98
Tangible Book Value per Share		 $0.32 $0.17 $0.01 $8.76 $3.27 $4.44 $5.04 $6.08 $4.16 $3.57 $6.98
Total Capital		 8.99 4.71 0.20 22 76 12 47 64 98 94 183
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -11 -6.57 -2.49 -26 -78 -14 -51 -68 -104 -95 -185
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.07 -2.32 -2.74 -4.00 -2.72 -3.23 -4.18 -4.12 -6.66 -1.54 -2.13
Debt-free Net Working Capital (DFNWC)		 8.49 4.24 -0.25 22 76 11 47 64 97 93 183
Net Working Capital (NWC)		 8.49 4.24 -0.25 22 76 11 47 64 97 93 183
Net Nonoperating Expense (NNE)		 1.48 1.36 1.48 1.84 1.33 1.38 0.84 1.01 3.77 2.10 2.43
Net Nonoperating Obligations (NNO)		 -11 -6.57 -2.49 -26 -78 -14 -51 -68 -104 -95 -185
Total Depreciation and Amortization (D&A)		 0.10 0.09 0.08 0.08 0.08 0.09 0.09 0.09 0.00 0.12 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 -3,330.65% -3,416.18% -3,652.00% -5,332.00% -4,460.66% -46,100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 13,687.10% 6,238.24% -332.00% 29,170.67% 123,973.77% 156,128.57% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 13,687.10% 6,238.24% -332.00% 29,170.67% 123,973.77% 156,128.57% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.40) ($2.72) ($57.12) ($2.76) ($0.33) ($1.64) ($1.31) ($0.48) ($0.24) ($0.22) ($0.24)
Adjusted Weighted Average Basic Shares Outstanding		 1.62M 1.65M 81.52K 2.16M 22.08M 2.62M 4.06M 10.64M 38.60M 41.52M 49.39M
Adjusted Diluted Earnings per Share		 ($3.40) ($2.72) ($57.12) ($2.76) ($0.33) ($1.64) ($1.31) ($0.48) ($0.24) ($0.22) ($0.24)
Adjusted Weighted Average Diluted Shares Outstanding		 1.62M 1.65M 81.52K 2.16M 22.08M 2.62M 4.06M 10.64M 38.60M 41.52M 49.39M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($57.12) $0.00 $0.00 $0.00 ($1.31) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.65M 1.65M 149.85K 2.57M 23.45M 9.37M 10.56M 23.22M 25.60M 33.86M 34.35M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.93 -3.04 -3.19 -4.11 -6.03 -2.90 -3.88 -4.05 -11 -6.86 -9.51
Normalized NOPAT Margin		 -28,050.00% -5,627.22% -45,500.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -38,650.00% -8,142.59% -66,585.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -9.92% -9.36% -9.55% -14.51% -13.25% -13.66% -27.09% -14.04% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Benitec Biopharma’s financial statements show a well-capitalized but still pre-commercial biotechnology company. Cash and equivalents increased from $6.6 million in March 2023 to $184.8 million in March 2026, largely reflecting equity and other financing activities. At the latest reported balance-sheet date, total liabilities were only $3.7 million versus $183.3 million of equity, giving the company substantial financial flexibility.

  • Significant cash buildup: Cash rose from $67.8 million in September 2024 to $94.5 million in September 2025 and $184.8 million in March 2026. This provides a considerably longer funding runway than the company had several years ago.
  • Strong balance-sheet liquidity: Q3 2026 current assets totaled $186.0 million compared with $3.3 million of current liabilities, implying an exceptionally high current ratio and limited near-term balance-sheet pressure.
  • Minimal debt burden: Total liabilities were $3.7 million at March 31, 2026, with no reported interest expense in the latest income statement. This reduces the risk that rising borrowing costs will further pressure results.
  • Interest income is partially offsetting operating losses: Interest and investment income increased to $1.6 million in Q3 2026 from $1.0 million in Q1 2026, reflecting the benefit of the company’s larger cash balance.
  • Research spending remains substantial: Research and development expense increased from $2.2 million in Q3 2022 to $6.3 million in Q3 2026. This may support development of Benitec’s pipeline, but it has not yet translated into reported revenue.
  • Cash use is partly affected by noncash items: Q4 2026 included $6.3 million of noncash adjustments, helping operating cash flow of negative $4.9 million compare favorably with the $12.8 million net loss. Investors should distinguish accounting losses from actual cash consumption.
  • No meaningful revenue generation: Reported revenue was zero in Q1 and Q3 2026, as well as in the comparable 2025 and 2024 periods. The company remains dependent on financing and investment income rather than commercial operations.
  • Persistent net losses: Benitec reported net losses of $4.7 million in Q4 2024, $9.0 million in Q1 2026, $11.9 million in Q3 2026 and $12.8 million in Q4 2026. Retained earnings remained negative at $260.9 million as of March 2026.
  • Operating cash flow remains negative: Operating cash flow was negative in every presented period, including negative $3.4 million in Q1 2026 and negative $4.9 million in Q4 2026. Continued cash burn means the company may eventually need additional capital if development spending rises or clinical programs extend.
  • Shareholder dilution is a major risk: Weighted-average basic shares increased from 1.4 million in Q4 2023 to 41.5 million in Q1 2026 and 49.4 million in Q3 2026. The increase reflects the company’s reliance on equity financing and can reduce each existing shareholder’s ownership percentage.

Overall, Benitec’s liquidity has improved dramatically, and the company appears to have limited leverage and a sizable cash reserve. However, the financial statements do not yet show an operating business: revenue is absent, losses are growing, and operating cash flow remains negative. For investors, the key catalysts are successful clinical or pipeline progress and eventual commercialization, while the principal risks are continued dilution, rising research costs and the need to convert development spending into revenue.

09/19/26 07:43 PM ETAI Generated. May Contain Errors.

Benitec Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Benitec Biopharma's financial year ends in June. Their financial year 2026 ended on June 30, 2026.

Benitec Biopharma's net income appears to be on an upward trend, with a most recent value of -$45.55 million in 2026, falling from $2.61 million in 2019. The previous period was -$37.92 million in 2025. See Benitec Biopharma's forecast for analyst expectations on what's next for the company.

Benitec Biopharma's total operating income in 2026 was -$51.19 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $51.19 million

Over the last 7 years, Benitec Biopharma's total revenue changed from $12.20 million in 2019 to $0.00 in 2026, a change of -100.0%.

Benitec Biopharma's total liabilities were at $5.61 million at the end of 2026, a 144.2% increase from 2025, and a 112.4% increase since 2019.

In the past 7 years, Benitec Biopharma's cash and equivalents has ranged from $2.48 million in 2023 to $179.97 million in 2026, and is currently $179.97 million as of their latest financial filing in 2026.

Over the last 7 years, Benitec Biopharma's book value per share changed from 19.37 in 2019 to 5.15 in 2026, a change of -73.4%.


Related Companies

Financial statements for NASDAQ:BNTC last updated on 9/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel